Jozef Marenčák
Prostate cancer (PC) is the most frequent solid neoplasm in Europe and therefore is regarded as one of the major medical problems in male population. PC is extremely complicated and interindividual different tumour. The method of treatment depends on several factors, but mainly on the stage of prostate cancer. The term Hormone resistant (refractory) prostate cancer (HRPC) was used in older terminology. HRPC is cancer that progresses despite castrate levels of testosterone achieved androgen deprivation therapy (ADT), which is resistant to any hormonal therapy. Currently there is increasingly used (instead of name HRPC) name CRPC – so called PC resistant for castration (CRPC – castration resistant prostate cancer), which is still able to respond to certain hormonal manipulation, although it meets the criteria for HRPC. Objectives of article: to provide information to the general medical community (and especially urologists and oncologists) mainly about a treatment of complicated issues of CRPC; basic data on the current and future possibilities of such therapy; to increase basic knowledge about CRPC treatment which should improve the care of patients with advanced PC.